In this model of postmenopausal arthritis, YSJB administration improved arthritis progression and prevented bone destruction by reducing osteoclastogenesis and regulating the expression of ephrinB2, ephB4, and NFATc1 in the BM. Here, EPHB4 is linked to Arthritis.